Natural Alternatives International price to free cash flow NAII
Market value divided by free cash flow over the last twelve months, since 2012.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 21.4×
- Feb 2026
- 9-year median
- 9.9×
- 9-year range
- 2.7× to 256×
- Peer median
- 4.9×
Natural Alternatives International's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.
It was last meaningful in Feb 2026, at 21.4×.
On the days it had one over the last 9 years, its median was 9.9×, from 2.7× in Aug 2024 to 256× in Feb 2019.
Price to free cash flow over time
The dashed line is the 9-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 21.4× | 19.7× | 28.8× |
| 2025 | 20.9× | 7.0× | 22.2× |
| 2024 | 3.4× | 2.7× | 9.0× |
| 2023 | 4.4× | 4.1× | 4.4× |
| 2022 | n/m a value too high to mean anything | ||
| 2021 | 5.5× | 5.2× | 13.2× |
| 2020 | 78.7× | 73.6× | 87.0× |
| 2019 | 74.9× | 47.9× | 256× |
| 2018 | 210× | 6.4× | 224× |
| 2017 | 6.4× | 6.3× | 10.9× |
| 2016 | 21.1× | 18.5× | 48.3× |
| 2015 | 44.5× | 7.5× | 47.0× |
| 2014 | 23.9× | 15.4× | 77.7× |
| 2013 | 47.5× | 4.4× | 48.4× |
| 2012 | 24.9× | 24.9× | 30.0× |
Against its peers
Companies in Chemicals nearest Natural Alternatives International's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| NAIINatural Alternatives International | n/m |
| BTMDbiote | 1.9× |
| FTLFFitlife Brands | 7.8× |
| NAGENiagen Bioscience | n/m |
| Peer median | 4.9× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Natural Alternatives International
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.